Fabry's disease is a sphingolipid storage disorder which is caused by mutations within the gene responsible for the expression of the lysosomal hydrolase, oc-galactosidase A ( 1). The enzyme defect results in the progressive deposition of uncleaved glycosphingolipids within lysosomes of endothelial, perithelial and smoothmuscle cells. The major clinical features may be divided into cutaneous lesions (angiokeratoma), ophthalmological abnormalities (corneal dystrophy), neurological abnormalities, cardiovascular diseases and renal involvement. A variety of techniques allowed the structural gene responsible for production of mature a-galactosidase A to be localized to the middle of the long arm of the X chromosome, Xq22 (2) . Point mutation within the gene, and partial or complete gene deletions, result in the classical phenotypic expression of the disease. No immunologically detectable or catalytically active enzyme protein is found in these patients. Elucidation of the genomic structure of the a-galactosidase A gene and its organization have facilitated the investigation of the molecular lesions producing these defects. Since most of a-galactosidase A gene mutations have been "private" occuring only in single pedigrees, the accurate identification of specific molecular defects in individual families would be impractical and may not be necessary. The unifying abnormality in all affected tissues is the accumulation of intracellular glycosphingolipid. The most striking renal changes are present in glomeruli, although tubules and blood vessels are also abnormal. Glomerular visceral epithelial cells are enlarged and vacuolated. The vacuoles generally are small and uniform and impart a "honeycomb" appearance to these cells (3) (4) (5) .
See also p 646. Routine immunoflurescence microscopy is typically negative, except in glomeruli with advanced lesions, such as segmental sclerosis. In these instances, IgM, C3 and Clq may be present in capillary walls and mesangial regions in a segmental distribution and granular pattern. Electroscopically, osmiophilic inclusions are always present in lysosomes and are surrounded by a single membrane,although larger inclusions may be rarely found in the cytoplasm (6) . The inclusions which range from 0.3 to 10 |im in diameter, are round and composed of concentric whorls of dense layers, imparting an onion skin appearance, as Shirai and colleagues described (5). This fine structure is considered to be characteristic of stored glycolipids.
Renal dysfunction often presents with mild proteinuria (0.5 to 2.0 g/24h), usually beginning during the third decade of life. Uremia and hypertension develop most commonly in the fourth and fifth decades (7). Renal failure is most commomin hemizygotes, but heterozygotes with end-stage renal disease are not rare. Nephrotic range proteinuria is unusual. In the absence of proteinuria, oral fat body on examination with bright field microscopy suggests the possibility of the presence of a lipid storage disease. Mild microhematuria has been reported. The diagnosis of Fabry's disease may be madeon the basis of clinical features of the disease and changes seen on slitlamp ophthalmoscopy, with confirmation by the demonstration of absent or low residual oc-galactosidase A activity in peripheral blood leukocytes or cultured fibroblasts. Most female carriers of the disease are asymptomaticand their identification may be unreliable. The light microscopic lesions of vacuolated glomerular visceral and tubular epithelial cells are nonspecific but suggest a storage process. The finding of urinary myelin bodies or within lysozome in renal tubular cells would be helpful for the diagnosis. Until dialysis and transplantation became available, there wasno specific treatment for this condition and the average age at death caused by uremia was 42 years. With renal replacement therapy mortality from cerebrovascular and cardiovascular involvement is nowmore common. There are no effective ways to delay the progression of renal or cardiovascular disease, but the early instigation of antihypertensive therapy is advocated. Since deposition of sphingolipid in the vascular endothelium mayactivate platelets, contributing to embolic or thrombotic cerebrovascular events, the early use of antiplatelet agents such as aspirin would seemrational. Enzymereplace-ment therapy using human plasma or purified a-galactosidase has been explored (8, 9) . Such treatment remains experimental. The large scale production of the enzymeusing a genetic method would potentiate the development of trials to evaluate short-and long-term clinical benefits of enzyme replacement therapy.
The main indication for renal transplantation in Fabry's disease is as for renal failure. It has also been undertaken in an attempt to determine whether the transplant could provide sufficient normal enzymefor substrate metabolism, either within the kidney or by release of enzyme into the circulation (10).
Symptomaticimprovementhas been observed. Recurrent deposition of glycosphingolipid within renal allograft has not been reported, although reaccumulation is slow and often minimal (1 1). Early diagnosis would prevent muchpersonal distress and facilitate referral for genetic counseling.
Seiya Okuda, MD
